GlassScriptPhysician profile
Harkanwal Dhillon
NPI 1538327721
$1,075.48
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $176 · 2021: $68.24 · 2022: $283.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $254.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $169.11 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $151.35 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $102.94 | 2019-2022 | |
| Akebia Therapeutics INC | $87.09 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $60.36 | 2022 | |
| Mallinckrodt Enterprises LLC | $44.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $35.86 | 2020 | |
| Daiichi Sankyo INC. | $32.49 | 2019-2022 | |
| Amgen INC. | $31.83 | 2022 | |
| Shire North American Group INC | $23.24 | 2019 | |
| Baxter Healthcare | $20.15 | 2019 | |
| Genentech USA, INC. | $17.43 | 2019 | |
| Calliditas Therapeutics US INC. | $16.10 | 2022 | |
| Travere Therapeutics, INC. | $16.04 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harkanwal Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.